Evommune, Inc.
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| – | – | – | |
| – | +28.7% | +7.9% | |
| – | – | – | |
| – | +122.0% | -155.5% | |
| – | -25.4% | +167.0% | |
| – | -91.8% | +2,787.7% | |
| – | – | – | |
| – | -22.5% | +346.7% | |
| – | -144.0% | – | |
| – | – | – |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.